After two years of controversy over the cost of hepatitis C treatments, the fast-growing market is poised to undergo a price war.
Late Thursday, Merck received Food and Drug Administration approval for its Zepatier medication and set a list price of just $54,600 for a 12-week course of treatment. This is considerably lower than the cost of rival medicines that have helped spark national outrage over prescription drug pricing.
About the Author Reprints
Will it work on type 3 Hep c